[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drugs in Development, 2021

March 2021 | 305 pages | ID: T77814251E44EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drugs in Development, 2021

SUMMARY

According to the recently published report 'Tyrosine Protein Kinase JAK1 - Drugs in Development, 2021'; Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 51 molecules. Out of which approximately 50 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.

The report 'Tyrosine Protein Kinase JAK1 - Drugs in Development, 2021' outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 12, 11, 13 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Infectious Disease, Central Nervous System, Cardiovascular, Genetic Disorders, Hematological Disorders, Hormonal Disorders, Metabolic Disorders, Ophthalmology and Women's Health which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, Psoriasis, Systemic Lupus Erythematosus, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Coronavirus Disease 2019 (COVID-19), Myelofibrosis, Vitiligo, Graft Versus Host Disease (GVHD), Inflammation, Inflammatory Bowel Disease, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Ankylosing Spondylitis (Bekhterev's Disease), Asthma, Diffuse Large B-Cell Lymphoma, Hidradenitis Suppurativa, Multiple Sclerosis, Peripheral T-Cell Lymphomas (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Bronchiolitis Obliterans, Chronic Lymphocytic Leukemia (CLL), Cytokine Release Syndrome (Cytokine Storm), Dermatitis (Eczema), Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Psoriatic Arthritis, Sicca Syndrome (Sjogren), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Triple-Negative Breast Cancer (TNBC), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lung Injury, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Aicardi-Goutieres Syndrome (AGS), Androgenic Alopecia, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Arthritis, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Hyperplasia, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Endometrial Cancer, Epstein-Barr Virus (HHV-4) Infections, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Graves Diseases, Hairy Cell Leukemia, Hemophagocytic Lymphohistiocytosis, Hepatocellular Carcinoma, Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Idiopathic Pulmonary Fibrosis, Juvenile Arthritis, Keratoconjunctivitis Sicca (Dry Eye), Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lipodystrophy (Lipoatrophy), Lupus Erythematosus, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Myeloproliferative Disorders, Myxoid Liposarcoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Oligoarticular Idiopathic Juvenile Arthritis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Plaque Psoriasis (Psoriasis Vulgaris), Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polycythemia Vera, Polymyalgia Rheumatica (PMR), Prurigo, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Skin Cancer, Solid Tumor, Spondyloarthritis (Spondyloarthropathy), Squamous Cell Carcinoma, Synovial Sarcoma, Systemic Idiopathic Juvenile Arthritis, T-Cell Lymphomas, Takayasu Arteritis, Thrombocythemia Myelofibrosis and Transitional Cell Carcinoma (Urothelial Cell Carcinoma). Global

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Indications, 2021 (Contd..3)
Number of Products under Development by Indications, 2021 (Contd..4)
Number of Products under Development by Indications, 2021 (Contd..5)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Products under Development by Companies, 2021 (Contd..8)
Products under Development by Companies, 2021 (Contd..9)
Products under Development by Companies, 2021 (Contd..10)
Products under Development by Companies, 2021 (Contd..11)
Products under Development by Companies, 2021 (Contd..12)
Products under Development by Companies, 2021 (Contd..13)
Products under Development by Companies, 2021 (Contd..14)
Products under Development by Companies, 2021 (Contd..15)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AbbVie Inc, 2021
Pipeline by Aclaris Therapeutics Inc, 2021
Pipeline by Alexion Pharmaceuticals Inc, 2021
Pipeline by Ashvattha Therapeutics LLC, 2021
Pipeline by Astellas Pharma Inc, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by Celon Pharma SA, 2021
Pipeline by Concert Pharmaceuticals Inc, 2021
Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Galapagos NV, 2021
Pipeline by GlaxoSmithKline Plc, 2021
Pipeline by Han Wha Pharma Co Ltd, 2021
Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2021
Pipeline by HK inno.N Corp, 2021
Pipeline by Impetis Biosciences Ltd, 2021
Pipeline by Incyte Corp, 2021
Pipeline by Japan Tobacco Inc, 2021
Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Pipeline by Jiangsu Simcere Pharmaceutical Co Ltd, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by Nippon Shinyaku Co Ltd, 2021
Pipeline by Novartis AG, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Sareum Holdings Plc, 2021
Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2021
Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021
Pipeline by Sierra Oncology Inc, 2021
Pipeline by Theravance Biopharma Inc, 2021
Pipeline by TLL Pharmaceutical LLC, 2021
Pipeline by Wuxi Fuxin Pharmaceutical Research and Development Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Discontinued Products, 2021
Discontinued Products, 2021 (Contd..1)

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021


More Publications